Background: In addition to being associated with gout, elevated uric acid levels are linked to obesity and atherosclerosis with cardiovascular disease and to neuropathy, which could cause falls. Raised levels are also commonly associated with reduced renal function, which would be expected to increase fracture risk. Results: Recent cohort studies in both men and women have found positive correlations between serum uric acid and BMD, and a lower risk of fractures including major osteoporotic fractures in persons with uric acid levels in the upper normal range, even after adjustment for body weight. Upper range normal uric acid levels have recently been found to be predictive of favourable hip geometry. However, others have reported an increased risk of hip fractures in men with uric acid levels in the highest quartile. While high normal or mildly elevated uric acid levels could be associated with good skeletal health and reduced risk of fracture, even after adjustment for weight differences, gout has been found be associated with excess risk of fractures, especially more severe gout necessitating continuous allopurinol treatment. It is not known if the fracture risk is explained by reduced BMD, inferior bone quality with an altered fracture threshold or by increased risk of falling.
Conclusion: There appears to be a discrepancy between on hand the association of high normal or mildly elevated uric acid levels with increased BMD and, in the majority of cohorts, a reduced risk of fractures and on the other hand increased risk of fracture as has been found in patients with gout requiring allopurinol treatment. Further studies are needed to establish if the relationship between uric acid and fracture risk may be U-shaped, if the fracture threshold is altered in patients with gout and if allopurinol has an independent effect on bone health that could explain the discrepancy between the existing studies. HIV is a modern-day plague with an estimated 35 million people infected worldwide. In the developed world, the prognosis has been transformed with the advent of combination antiretroviral therapy and life expectancy has normalised. However, this has led to an increasing population of ageing adults with HIV, at risk of a range of metabolic and other age-related pathologies, including osteoporosis. This presentation will review the data describing the epidemiology of osteoporosis in HIV-infected adults, including studies of BMD and fracture. This will be discussed in the context of traditional risk factors but also the role of human immmunodeficiency virus itself, which has recognised in vitro effects on bone health, probably at least partly because of circulating proinflammatory cytokines. The role of antiretroviral therapy in bone health, which is controversial, will also be discussed. This presentation will encompass the current literature on HIV and bone and fracture risk with opportunity for interaction and questions from the audience. Inflammatory arthritis is associated with bony changes both locally, around affected joints, and systemically. Individuals with rheumatoid arthritis may suffer from joint erosions, periarticular osteopenia, and have an increased risk of osteoporosis and fracture. The ways in which we assess these skeletal manifestations is changing. In this session, important imaging techniques will be discussed with a focus on the assessment of bone microstructure. Bone health has conventionally been measured using DXA and this remains true for individuals with inflammatory arthritis. Fracture risk can subsequently be calculated using FRAX® with rheumatoid arthritis included as a risk factor which does not act solely through effects on areal BMD (aBMD). Novel imaging techniques, including high resolution peripheral quantitative computed tomography, may provide greater understanding of the specific sites of bone affected by inflammatory arthritis and better explain the additional fracture risk. Thus, there is a growing understanding of the importance of assessing bone disease in individuals with inflammatory arthritis and the implementation of therapies to minimise their burden. The appropriate utilisation of imaging techniques is an important step in the process. Objective: The vision of the National Osteoporosis Society (NOS) is a future without fragility fractures; to achieve this the charity's aim is to ensure that every person aged over 50 who breaks a bone is assessed for osteoporosis and managed appropriately through a fracture liaison service (FLS). To realise this, the NOS have developed a model to support and facilitate FLS development across the UK. Material and Methods: In 2014 the NOS brought together national and local stakeholders, clinicians and patient representatives to form the FLS Implementation Group (FLS-IG), to provide leadership and coordination across projects designed to increase FLS provision across the UK. Under the auspices of the FLS Implementation Group (FLS-IG), a range of online resources were developed to support FLS development and improvement, which include: FLS Clinical Standards; an FLS Implementation Toolkit to support providers and payers; and accredited training providing certification for fracture prevention practitioners. In addition, the NOS enlisted a team of service development managers with specialist clinical and commissioning experience to offer consultation and guidance at every step of the process, from pathway development, to successful funding of services. Advice on the most appropriate outcome measures and performance indicators, as well as effective data collection for service evaluation is also provided. These resources and support are all provided free of charge. Results: To date support from the NOS has enabled the successful funding of 7 FLS over a period of 9 months. This will provide FLS coverage to an additional cumulative population of over two million people and could potentially prevent up to 763 hip fractures over the next 5 y 1 .
NS3 HIV AND BONE HEALTH

NS5 MODEL OF SUPPORT FOR FLS DEVELOP-MENT
H
Conclusion:
Recognising that this enhanced model of support has been successful in driving forward the development and improvement of FLS across the UK, the NOS is committed to continuing to drive forward this programme of work to meet the aims of the charity. Objectives: Since conception, the Fracture Liaison Service (FLS) model for secondary fracture prevention can be applied in different settings -urban and rural, primary care and secondary care -across the UK, and indeed the world. However, equity of provision and quality is essential in order to achieve the potential benefits of preventing up to a quarter of all future hip fractures. The National Osteoporosis Society (NOS) set out to extend the coverage and improve the quality of FLS across the UK. Material and Methods: The NOS have mobilised an experienced team of specialist clinicians who are able to provide support to those who wish to develop or improve an FLS. The UK FLS Clinical Standards published in 2015 provide the core standards that every FLS should meet to ensure that optimal identification, investigation, information, intervention and integration with primary care are achieved, within a framework of quality, to the long-term benefit of fracture patients -the 5IQ approach. Using the standards, the team undertake a gap analysis against the standards with each site visited, to determine any gaps in service provision and identify areas for service improvement. The charity also offers a more comprehensive peer review of osteoporosis and metabolic bone services, which provides quality assessment and assurance of clinical care to improve performance, based around professional credibility and addresses areas of clinical governance, practitioner revalidation and service development. Results: To date the NOS are supporting quality improvement of FLS at over 60 sites across the UK; 44 gap analyses and 5 peer review visits have been undertaken. Both the gap analyses and the peer review visits have provided objective evidence to enable service improvement resulting in positive outcomes and facilitating service development. Conclusion: By utilising the published UK FLS Clinical Standards and disseminating evidence-based best practice, the NOS are facilitating quality improvement of FLS across the UK. This will ultimately reduce the future burden of fragility fractures whilst improving outcomes for patients through ensuring every person over the age of 50 has access to a gold standard service.
NS7 SOCIOECONOMIC COSTS AND BENEFITS
T. Jones 1 1 National Osteoporosis Society, Camerton, Somerset, United Kingdom Background: The National Osteoporosis Society has an ambition to ensure that the entire UK population has access to an effective Fracture Liaison Service (FLS). To achieve this, the charity has to overcome two barriers, firstly to make a strong, evidence-based case for investment in a health system that is financially constrained. Secondly, to overcome weaknesses in the process to develop and evaluate the business case for FLS. Principally these are a lack of skills and time to research, model and present the costs and benefits of an FLS in a clear and compelling way. Working closely with clinicians and payers across a large number of sites has helped us to develop a standard method of determining the costs and benefits for any population in the UK. Objective: This session will demonstrate the method of showing costs and benefits of FLS for a given population using available parameters. Material and methods: The session will include demonstration of two, pre-populated tools for estimating: 1. Benefits of FLS in terms of number and costs of fractures prevented 2. Cost of providing a service including nurse/doctor/administrative inputs and DXA scan costs Results: The methodology shows that the costs of providing an FLS are approximately 40 % of the expected benefits in health and social care. Conclusions: FLS is a cost-effective method for preventing secondary fragility fractures. The methodology, using population-based calculators, allows the creation of a compelling, evidence-based business case without the need for advanced skills in costing, modelling or other health economic techniques. The methodology used is transferrable to other nation's health and social care systems at national, regional or local level.
NS8 DISTAL BONE MICROSTRUCTURE
E. Biver Although it is well established that a T-score below 2.5 SD predicts fractures, a high proportion of fragility fractures occur in patients with osteopenia. One of the reason is that alterations of bone microstructure (as part of the definition of osteoporosis, a decrease in bone mass and alteration of bone micro-architecture leading to higher bone fragility and risk of fracture) are not captured in the measure of areal BMD by DXA. Peripheral volumetric BMD (vBMD) and cortical and trabecular bone microstructure can be assessed non-invasively in vivo at the distal radius and distal tibia, using a HR-pQCT suitable for in vivo studies in humans (Xtreme-CT, Scanco, Bassersdorf, Switzerland). Bone scans are performed at the non-dominant limb, unless a fracture was reported in the region of interest, with a resolution of 60-82 μm (depending of Xtreme-CT models), a short measurement time (about 3 min per bone site) and a low irradiation dose. Bone strength parameters (stiffness, failure load, and apparent modulus) can be estimated by finite element models created directly from the segmented HR-pQCT images. Alterations of bone microstructure, independent of areal BMD, have been shown in various contexts of bone fragility (diabetes, chronic kidney diseases, HIV, etc.) and discriminate osteopenic women with and without prevalent fragility fracture. Recent data in prospective cohorts (OFELY, Geneva Retirees Cohort) indicate that the decay of bone microstructure highly contributes to subsequent fracture risk. In the Geneva Retirees Cohort (GERICO), cortical bone microstructure alterations at the distal radius predict incident fractures independently of the classical tools used in clinical practice (i.e., DXA and FRAX). Data obtained in several large cohorts should provide population reference bases, which are missing up to now, for data interpretation of distal bone microstructure assessment at the individual level beyond DXA. However, HR-pQCT is currently dedicated to research purposes because of the low number of devices and the long duration of data analyses. For longitudinal analyses, the improvement of identification of the common region of interest should contribute to improve the reproducibility of microstructure bone parameter measurements. Objective: The measurement of various bone regulatory proteins has been developed over the last decades. These could provide an appreciation of both the pathophysiology of osteoporosis and of a modified level of fracture risk. Methods: Here, we review the role these proteins may have in the fracture risk assessment. Results: In a French cohort of postmenopausal women, the relative risk (RR) for fragility fracture was 1.88 (1.1; 3.2) among those women in the highest quartile of periostin concentrations, independently of prevalent fracture, age and BMD. The measurement of serum RANKL does not appear to reflect accurately the risk of fragility fracture or bone loss in postmenopausal women. In the Study of Osteoporotic Fractures osteoprotegerin (OPG) levels, which were about 30 % greater in postmenopausal women with diabetes than in those without diabetes, were not associated with baseline BMD or with subsequent fractures. In a nested case-control study among postmenopausal Caucasian women aged 50-79 at baseline in the Women's Health Initiative Observational Study, serum OPG levels were independently associated with a nearly twofold increased risk of hip fracture. A protective effect has also been observed in 1664 female patients from 95 nursing homes in Austria. In postmenopausal osteoporosis, a negative association of Dkk-1 with BMD has been reported. The relationship of serum sclerostin concentrations with fracture has been inconsistent across cohorts of postmenopausal women, and is probably of little clinical significance. In men, however, the relationship with fracture seemed to be of an opposite direction that in women, with greater levels being protective. Two prospective studies have analyzed the relationships between serum intact FGF-23 and fracture risk in elderly men, with the conflicting observation that increased baseline FGF-23 was associated with an increased risk of all fractures and vertebral fractures older Swedish men, but not in the American MrOS study. Conclusion: The predictive value of bone regulatory proteins to predict fracture has not been well established so far. Some of these provided promising results, that need to be confirmed once technical measurement issues are resolved. At least one-third of the population aged 65 years and over fall once or more annually; this rate increases with advancing age. Most nonvertebral fractures occur upon a fall. Besides the resultant fractures, falls among older people are devastating in terms of disability, morbidity, mortality and socioeconomic burden. From a fall-and-fracture reduction perspective, fall risk should be addressed along the continuum of care of aging adults. The etiology of falls is usually multifactorial. Previous falls, muscle weakness, and gait or balance disorders are the strongest risk factors for falls. Inability or difficulty to perform two or more tasks simultaneously, which may depend on executive functions, is also emerging as an important risk factor for falls. Clinicians should recognize the role of sarcopenia in determining both fall and fracture risks. Low lean mass, as defined with Baumgartner thresholds (i.e., appendicular lean mass -assessed by DXA-divided by height squared below 7.26 kg/m 2 for men and 5.45 kg/m 2 for women), was recently shown as a predictor of incident fractures, independently from FRAX ® , in our cohort GERICO of 65-year old communitydwellers. No single valid tool at present permits the reliable identification of individuals at increased risk for falls. Screening should first be based on a past history of falls. Simple tests can also help identify those with physical deficits who will benefit from an intervention. There is strong evidence that appropriately prescribed interventions can reduce falls. The identification of modifiable intrinsic and extrinsic risk factors is a crucial initial step to falls prevention. For high-risk individuals (i.e., particularly those who report recurrent or injurious falls or demonstrate abnormalities of gait and/or balance), multifactorial fall risk assessment followed by direct interventions tailored to the identified modifiable risk factors, in combination with a suitable exercise program, should be considered. Hospitalization affords a major opportunity to display such a complex direct intervention without referral. For selected patients a single intervention may be acceptable including, but not limited to, exercise/physical therapy, especially programs emphasizing balance and muscle strength/power training, and prescription of vitamin D. In the past, the emphasis in the treatment of osteoporosis and fracture prevention was mainly put on medication [bisphosphonates (alendronate, risedronate, ibandronate and zoledronic acid), strontium ranelate, teriparatide, denosumab, selective estrogen receptor modulators or SERMs, raloxifene and bazedoxifene, etc.] and supplementation with calcium and vitamin D. However, in the past two decades the medical community became more aware of the importance of physical activity, muscle mass and function, both in the prevention and treatment of osteoporosis, as well in childhood and adolescence as in adult life and geriatrics (when both bone and muscle decay and dysfunction are seen). On the website of the International Osteoporosis Foundation (IOF) for some time now a separate chapter can be found about exercise playing an important role in building and maintaining bone and muscle strength. Physical activity is difficult to be quantified and objectively measured. Moreover, it is more challenging if not problematic to find sponsors to finance such studies. Nevertheless, more recently several studies were published describing better and quantifiable techniques to evaluate the effect of physical activity, muscle mass and function on bone metabolism and osteoporosis. In this symposium an overview will be given of the importance of physical activity in the treatment, rehabilitation and prevention (primary, secondary and tertiary) of osteoporosis, falls and fractures. According to the WHO, physical activity is defined as any bodily movement produced by skeletal muscles that requires energy expenditure. Regular moderate intensity physical activity -such as walking, cycling, or participating in sports -has significant benefits for health. In osteoporosis, physical activities and non-pharmacological interventions could be of potential interest in primary (i.e. before the disease), secondary (i.e. at the early stage of the disease) or tertiary prevention (i.e. after fracture in osteoporosis). Indeed, disability is strongly associated with musculoskeletal conditions, such as low back pain or osteoporosis-related fracture. These diseases can have longterm impacts on the quality of life of the patients. The predominance of evidence on the effects of physical activity and rehabilitation interventions for osteoporosis suggests that they enable modest health related quality of life relief, reduced disability, and improved function. More researches are needed to identify the modalities (e.g. doses, volume, duration, type, combination) of physical activity that could be the most effective to improve quality of life and functional performance in subjects with osteoporosis. The combination and the potential added value of pharmacological and non-pharmacological treatment also need to be better investigated. However, the exact modalities of physical activities need to be defined but depend of the disease and of the stage of its management (primary, secondary or tertiary prevention). Fractures can be prevented by both increasing bone strength and by reducing falls risk. There is some evidence that low load activities such as walking have at most a modest effect on BMD while high impact exercise or high intensity resistance training produce the greatest response (Kohrt et al. 2004, Med Sci Sports Exerc; Howe et al. 2011, Cochrane Review) . Muscle strengthening and balance retraining exercises of sufficient duration have been shown to reduce falls. Although there is some evidence that that exercises designed to reduce falls can also reduce fractures (Cochrane review 2012), evidence on whether they can increase bone strength is sparse. Participants were recruited from the larger ProAct65+ trial, a major primary care-based pragmatic 3-arm randomized controlled trial of 1256 men and women comparing group exercise and homebased exercise with usual care in older people aged 65 years and over (Iliffe et al. 2015, Br J Gen Pract) . Both the group exercise (Falls Exercise Management or FaME) and home exercise (Otago Exercise Programme or OEP) arms are evidence based programmes designed to reduce falls (Campbell et al. 1999, JAGS; Skelton et al. 2005 , Age Ageing). In the bone sub-study of the ProAct65+ trial (n = 319), BMD, bone mineral content (BMC) and structural properties were measured before and after the 24-week intervention in a sample of participants in all 3 arms. Ninetytwo % of participants (N = 293) completed the bone sub-study of the trial. The OEP group completed 58 (SD ± 43) min/week of home exercise, while the FaME group completed 39 (±16) and 30 (±24) min/week of group and home exercise respectively, and the usual care group reported 15 (±32) min/week of home exercise. Femoral neck BMD changes did not differ between treatment arms: mean (95%CI) effect sizes in OEP and FaME relative to usual care arm were −0.003 (−0.011,0.005) and −0.002 (−0.010,0.005) g cm − 2, respectively (p = 0.44 and 0.53). There were no significant changes in BMD or BMC at other skeletal sites, or in structural parameters (Duckham et al. 2015 , Age Ageing). These results suggest that currently used falls prevention exercise programmes may not improve bone strength in older people. To increase bone strength, programmes may need to be of longer duration or require additional exercises that exert higher strains on bone. The overall positive effects of physical activity and regular exercise are well known in the general population including clear benefits on bone health and prevention of falls and fractures. We do propose a critical review of available data regarding physical activity, exercise and other related interventions aimed at preventing and/or treating osteoporosis in patients in various types of rehabilitation programmes. The presentation will focus on a very specific population of patients entering focused stationary and ambulatory rehabilitation programmes aimed at ameliorating their overall physical capacity, functioning and quality of life according to the ICF (International Classification of Functioning, Disability and Health), WHO, 2001) . The patients presenting with various types of neurological, pulmonary, cardiac, musculoskeletal diseases and conditions are being sent to highly specialized rehabilitation units after initial stabilisation of their health condition. The majority of these patients will be aged, frail, deconditioned with low BMI, often with sarcopenia and a poor bone metabolic balance, a decreased BMD with or without previous osteoporotic fracture(s). These problems might be at higher prevalence with some types of underlying medical problems and types of rehabilitation. As a consequence, this specific population of patients definitively presents with a higher risk of osteoporosis, falls and fractures as compared to an age and sex matched population. We intend to address the various preventive and therapeutic strategies aimed at reducing the burden of osteoporosis with a focus on physical activity, exercise and other related interventions. Acknowledgments: the author would like to specially thank the whole multidisciplinary rehabilitation team (physical and occupational therapists, nurses, medical doctors) of the CVP (Valais Center of Pneumology) in Crans-Montana for their continuous support.
NS9 ROLE OF CIRCULATING BONE REGULATORY PROTEINS TO PREDICT FRACTURE RISK
NS10 FALLS RISK ASSESSMENT
NS12
NS13 CAN EXERCISE INTERVENTIONS DESIGNED TO REDUCE FALLS IMPROVE BONE QUALITY
NS15 THE RELEVANCE OF COLLAGEN FOR THE PATHOGENESIS OF MUSCULOSKELETAL DISEASES
S. H. Scharla Collagen is a multifunctional protein found in nearly 90 % of the body. Moreover, 25-30 % of the total protein amount of the human body consists of collagen. It is synthesized as procollagen and, after various intracellular modifications such as hydroxylation of proline and lysine and glycosylation of other amino acid residues, three single procollagen sub-chains are bound into a triple helical structure. Procollagen is further processed outside the cell: It is cleaved by enzymes and the triple helical-structures are then arranged in fibril bundles, which are characterized by containing domains with predominantly three amino acids, glycine, proline and hydroxyproline. 85 % of the 22 known types of collagen are type I, II or III collagen generated by connective tissue cells like fibroblasts, chondrocytes and osteoblasts. The collagen meshwork forms the basis of the extracellular matrix (ECM), and various structural macromolecules like proteoglycans or elastin are embedded in this meshwork. An intact ECM provides both tensile strength and flexibility of the connective tissue. For the maintenance of connective tissue functionality, a continuous turnover of the extracellular matrix is essential. With increasing age, a progressive loss of connective tissue occurs due to an imbalance between catabolic and anabolic processes. These pathophysiological changes eventually lead to degenerative diseases such as osteoporosis or osteoarthritis, and, together with age-related metabolic changes, might also promote sarcopenia. To address the cause of these wear and tear processes it is essential to counteract the progressive loss of the collagen matrix. Several pre-clinical and clinical studies have demonstrated that the supplementation of bioactive collagen peptides improves connective tissue metabolism and counteracts progressive tissue degeneration. It could be shown that collagen peptides are rapidly absorbed in the gastro-intestinal tract and that collagen-derived peptides reach the connective tissue where they can stimulate extracellular matrix synthesis. In recent years, a significant number of studies have demonstrated the positive effect of bioactive collagen peptide (BCP) supplementation on musculoskeletal health. Numerous RCTs on a total of 2400 patients suffering from osteoarthritis (OA) revealed a statistically significant reduction in pain and improved mobility after an oral BCP treatment. In addition, a clinical study demonstrated the positive effect of a long-term BCP supplementation on the extracellular matrix (ECM) of cartilage tissue. BCPs have excellent bioavailability and tend to accumulate in the connective tissue. It was demonstrated that specific collagen peptides stimulate the ECM biosynthesis of cartilage tissue. The antiinflammatory effect of collagen peptides was also discussed. It was assumed that the stimulatory effect of BCPs in particular provides symptomatic improvement in the treatment and prevention of osteoarthritis by counteracting progressive tissue degeneration. This was recently confirmed in two phase III RCTs on 340 women and men suffering from joint pain of the lower extremity. The data showed a statistically significant improvement after a 12-week BCP treatment compared with placebo. In both studies, joint pain during activity and at rest was markedly reduced. In addition to the positive effect of a BCP treatment on degenerative joint diseases, collagen peptide supplementation has also demonstrated its effectiveness on bone health. Investigations on human osteoblasts showed a pronounced stimulatory effect of BCPs on the biosynthesis of bone ECM macromolecules and a concurrent significant decrease in osteoclast activity. As a consequence, an increased production of organic bone material and a statically significant increase in BMD could be determined. This effect was recently confirmed in a clinical trial on 160 women suffering from osteoporosis or osteopenia. A BCP treatment over a period of 12 months led to a statistically significant BMD increase in the proximal femur and in the spine compared with placebo, as measured by DXA scans. In conclusion, the data suggest that a BCP supplementation could have a positive impact on maintaining or improving bone and joint health. Further long-term trials might assist in confirming the efficacy of a BCP treatment. According to the European Working Group on Sarcopenia in Older People (EWGSOP), the diagnosis of sarcopenia includes both, a low muscle mass and a low muscle function (strength or performance). In general, aging is associated with a decline in motor function, a reduction in muscle mass and a decrease in muscular performance. Consequently, a large number of elderly subjects suffer from sarcopenia. Sarcopenia is associated with an increased risk for falls and an overall prevalence for frailty. Therefore, an effective treatment of sarcopenia is of utmost importance to improve the quality of life and to reduce the risk of injuries and frailty in elderly subjects. Several investigations have shown that the onset of sarcopenia can be postponed and the progress decelerated by regular physical activity, mainly resistance exercise. Furthermore, it has been demonstrated that additional dietary proteins enhance the rate of post-exercise net muscle protein synthesis and decrease muscle protein breakdown following resistance exercise. In a recent meta-analysis, Cermak et al. showed that the combined effect of resistance exercise and protein supplementation on free fat mass (FFM) and muscle strength was significantly higher in protein-supplemented subjects. It is generally believed that the proteins applied should be high in branched chain amino acids, in particular leucine, which is known to activate several intracellular signal transduction pathways involved with initiating translation such as the mTOR signalling pathway. However, recent investigations have shown that also the supplementation of collagen peptides led to a significant increase in muscle mass following resistance exercise. Collagen is an extracellular protein that accounts for 25-30 % of the total protein amount within the human body. The effect of collagen supplementation on muscle mass has been demonstrated in aged and middle-aged sarcopenic subjects and was comparable to the effect of whey supplementation. In conclusion, results from current studies support the use of collagen peptides to improve gains in muscle mass following resistance exercise. Furthermore, it has been shown that the reduction in fat mass was also significantly higher in collagen-supplemented subjects. Therefore, the effect of collagen peptides in improving muscle mass and functional outcome measures in subjects with sarcopenia yields promising results and should be further investigated.
NS16 THE BENEFICIAL EFFECT OF
NS17 NEW CONCEPTS FOR THE MANAGEMENT OF
NS18 RISK FACTORS FOR FRACTURE IN WOMEN WITH BREAST CANCER
J.-J. Body Women with breast cancer have an increased prevalence and incidence of fractures. In postmenopausal women, this increased risk of fracture has become most evident following the use of aromatase inhibitors (AIs) as standard adjuvant therapy. The aromatase enzyme, which is blocked by AIs, converts androgens into estrogens. This conversion is the main source of endogenous estrogens in post-menopause. AI-induced bone loss occurs throughout the duration of therapy, averaging approximately 2 % per year. Moreover, pQCT data indicate that effects of AIs on bone strength and on cortical bone have been substantially underestimated by DXA. All AIs have been associated with an increased fracture risk. The incidence of fractures is at least 33-43 % higher in AI-treated patients than in tamoxifen-treated patients, and this increase in fracture risk is maintained for the duration of AI therapy. Importantly, fractures occurring in all clinical trials were reported as adverse events of oncology trials, thus not representing primary endpoints of the studies, which is a likely source of underreporting and underestimation of fracture incidence. In pre-menopausal women, adjuvant therapies, especially chemotherapy, can induce premature menopause or are specifically designed to suppress ovarian function and reduce circulating estrogen levels. Chemotherapy-induced ovarian dysfunction appears to be quite common, as between 25 % and 100 % of these women may experience early menopause or amenorrhea. In this setting, age is an important determinant of which patients are more likely to experience ovarian failure. In addition to bone loss associated with low estrogen levels, cytotoxic chemotherapy can have a direct negative effect on bone metabolism. Tamoxifen alone and in combination with ovarian function suppression are standards of care for women with estrogen receptor-positive breast cancer. In women receiving combined therapy with AI and a GnRH agonist, the annual bone loss rate increases up to 7.0 % and tends to be even higher in women who experience premature menopause secondary to chemotherapy. In summary, most adjuvant therapies in pre-or postmenopausal women with breast cancer lead to significant bone loss and increase the fracture rate. This bone loss may necessitate earlier pharmacotherapy than is indicated for postmenopausal osteoporosis. Osteoporosis is one of the most frequent diseases in postmenopausal women leading to an increased fracture risk due to the physiologic loss of the bone protective effects of estrogen. Hereby, several risk factors for fracture such as prevalent fracture, low BMD, age, low BMI, family history, tendency to falls, smoking, use of SSRIs, glucocorticoid use etc. have been identified. Additionally, the further reduction of endogenous estrogens with chemotherapy (CHT), GnRH-analoga or aromatase inhibitors (AI) continuously increases fracture risk. Breast cancer (BC) on the other hand is the most frequent cancer type in women. Recent reports indicated a continuous increased incidence while mortality, due to early diagnosis and treatment improvements is decreasing. Dependent on specific tumor characteristics, radiation, chemotherapy (CHT), antibody treatment as well as endocrine treatment has been introduced into the adjuvant clinical treatment setting. Some but not all of this cancer specific treatments interfere with bone turnover leading to an accelerate bone loss referred to as cancer treatment induced bone loss (CTIBL). Whereas CHT leads to an unspecific increased of bone resorption, Aromatase inhibitor (AI) reduces residual serum endogenous estrogen level and is associated with a decrease of BMD and increased fracture risk. Independent of the type of AI administered, bone loss is 2-3 fold increase compared to healthy, age matched postmenopausal controls. Therefore several guidelines have emerged to help managing CTIBL in women with BC including strategies to identify and treat those at highest risk for fractures. The talk will summarizes the current knowledge on CTIBL and fracturing risk and indicates current treatment guidelines and intervention options.
NS19 CURRENT TREATMENT GUIDELINES AND INTERVENTION OPTIONS
NS20 ADDITIVE EFFECTS OF ANTIRESORPTIVE TREATMENTS BEYOND OSTEOPOROSIS
R. E. Coleman 1 1 University of Sheffield, Sheffield, United Kingdom Metastasis prevention trials with bisphosphonates have reported variable outcomes in terms of disease recurrence with efficacy apparently influenced in breast cancer by age and menopausal status of the patients. We have shown that disease outcomes, both in patients and animal models of metastasis, are influenced by levels of reproductive hormones and this appears to explain the variable results seen in individual clinical trials reported to date. In a recent initiative with the Early Breast Cancer Clinical Trials Group (EBCTCG), individual patient data from randomised trials that evaluated the effect of an adjuvant bisphosphonate on breast cancer outcomes were collected for metaanalysis. With 3,453 and 2.106 breast cancer recurrences and deaths respectively in 18,766 randomised women, we showed important clinical benefits. Bisphosphonates reduced first distant recurrence in bone (RR = 0.83; 95%CI 0.73-0.94, 2p = 0.004) and the significant interaction between treatment efficacy and menopausal status was confirmed. There were no demonstrable benefits in premenopausal women but in 11,767 postmenopausal women, highly significant reductions in bone recurrence (RR = 0.72; 95%CI 0.60-0.86, 2p = 0.0002) and breast cancer mortality (0.82; 95%CI 0.73-0.93, 2p = 0.002) were seen. These findings are changing clinical practice and could eventually be expected to prevent 1000 deaths per year in the UK alone. In other common malignancies, notably prostate cancer and lung cancer, similar benefits have not been seen and we need to understand the reasons why modulation of the bone microenvironment by bisphosphonates is less effective in other disease settings. Randomised trials with denosumab also suggest that this bone-targeted agent can reduce disease recurrence and delay bone metastasis in early breast cancer and castration resistant prostate cancer respectively. Definitive study results are awaited, however, before this agent can be recommended as a disease modifier. Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom FRAX ® is a computer based algorithm (www.shef.ac.uk/ FRAX) that calculates the 10-year probability of a major fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip. Fracture risk is calculated from age, BMI and well validated dichotomized risk factors. Femoral neck BMD can be optionally input to enhance fracture risk prediction. The first 8 models were launched in 2008 and there are currently more than 50 country-specific models available covering 79 % of the world population. With the increasing geographic representation of FRAX, uptake has risen progressively and there are upwards of 3 million calculations undertaken each year. A probability calculation is of no use unless guidance is provided on its use. This demands the setting of intervention thresholds -namely the fracture probability above which treatment can be recommended. This depends critically on the development of country-specific assessment guidelines that incorporate FRAX and reimbursement policies that are attuned to the guideline. As expected, there is a lag between the availability of FRAX and its incorporation into assessment guidelines. In the countries of the European Union, approximately half now mention FRAX in the guideline and, of these, about half give explicit instructions on its use. As expected, the uptake of FRAX is heterogeneous in different countries and is higher in those with established assessment guidelines. The future development of FRAX thus depends critically on national rather than international initiatives. The purpose of FRAX is to better target interventions to individuals at high risk. The performance characteristics of FRAX based guidance can be assessed. In many countries, treatment is recommended in individuals with a prior fragility fracture and treatment also recommended in those whose fracture probability exceeds that of a woman with a prior fracture (irrespective of prior fracture). Individuals identified in this way have on average higher fracture risks than individuals identified on the basis of prior fracture, low BMD or integrated algorithms such as that of the US National Osteoporosis Foundation. Thus, FRAX has the potential to decrease the burden of fractures but its success or failure depends on its judicious application by thought leaders in individual countries. Oregon Osteoporosis Center, Portland, OR, United States FRAX was incorporated into an update of the US National Osteoporosis Foundation (NOF) guidelines simultaneously with its availability in 2008. Earlier NOF guidelines recommended treating virtually all postmenopausal women with a T-score of ≤ −1.5. These guidelines were not widely accepted, and many professional societies had their own, more conservative guidelines, resulting in confusion about who to treat. The 2008 NOF guidelines recommend treatment for all postmenopausal women, and men age 50 and older, who have a history of vertebral or hip fracture or who have osteoporosis by BMD criteria. In those patients with T-score values between −1 and −2.5), treatment is recommended if 10 year FRAX probability of hip fracture is ≥3 % or of major osteoporotic fracture of ≥20 %. These guidelines appropriately target patients at high risk for fracture while avoiding treatment in healthy young women with low BMD as their only risk factor. The revised NOF guidelines are endorsed by major professional societies and by many health plans. Agencies such as the US Preventive Services Task Force and the Agency for Healthcare Research and Quality have suggested that FRAX, without BMD, be used to identify patients for bone density testing. FRAX software is available on most DXA machines in the US, and more than 5 million FRAX calculations have been made in the US since June 2011. (In 2010, there were 40.3 million people age ≥65 in the US.) The NOF guidelines have been criticized for increasing the number of patients ≥65 identified for therapy, but the proportion of younger postmenopausal women identified for treatment was markedly reduced by the FRAX-based guidelines. The true clinical impact of FRAX on treatment is unknown. Its effects have been swamped by marked concern in the US among patients and physicians about the long-term safety of osteoporosis therapy, decreased concern about the importance of osteoporosis, and by refusal of some insurance plans to pay for therapy in patients who lack BMD criteria for osteoporosis. Additionally, there is limited awareness by many primary care physicians of the existence of FRAX-based guidelines. While availability of FRAX has provided clarity about who should be treated, including men, poor awareness and reimbursement policies have limited the impact of FRAX in the USA. Whether or not FRAX should be calibrated for different races in LATAM depends on whether or not there is a causal relationship between "race", osteoporosis, and risk of fragility fractures in LATAM. More than 80 % of the medical literature uses race or ethnicity as a general term with no specific definition; therefore, to define "race" in this context is mandatory. More than 500 years ago, race was used to designate groups of humans marked by their common origins or shared physical characteristics. For decades, anthropologists and geneticists have devoted their time in the study of human race. Since the 19th century, race has been used to define different groups of humans based on biological characteristics such as skin color, hair distribution etc.; blood groups and antibody types were added during the 20th century, and currently ancestry and evolution uses genetic materials finding new levels of detail regarding the biological human variation. On the other hand, the concept of race has evolved as well to be named a "cultural construction" including social behavior, where race is viewed as a social construct with biological traits. The "ecosocial theory" of disease distribution was developed including both biological traits, and social environment. For the purpose of this presentation, race will be defined accordingly with the "ecosocial theory", from this perspective; the risk factors included in FRAX will be analyzed. The vast majority of the LATAM population is born from a mix of Europeans of Latin origin and native Indians called "mestizos". From this mixture, 16 different combinations were described in Mexico and 134 in Brazil. This wide variation of race classification does not appear to have any impact in the health determinants of osteoporosis. On the other hand, epidemiological reports from Latin-American countries has shown that patterns of hip fractures are quite similar to those in the rest of the world, however, important differences in the incidence of fractures are found. Most likely, these differences are related to heterogeneous death hazard ratio and differences in the life expectancy across countries. Death, life expectancy, and the epidemiology of fractures are needed in order to have a precise risk probability of fractures from FRAX. These variables seem like the main reasons of why it is important to calibrate the FRAX models for any given country. Other mayor fractures as clinical vertebral, forearm and humerus should be included to the FRAX algorithms since they help to build a more robust model of prediction, but only Mexico has complete information on other fractures. The uptake of FRAX in Europe is generally high but with a relatively wide variation. For example, there is high populationadjusted usage in Slovenia, Switzerland, Belgium and the UK but relatively low uptake in countries such as Serbia, Bulgaria and Germany. While low uptake might relate to the priority given to osteoporosis within healthcare provision of individual countries, the incorporation of FRAX into national guidance, combined with user friendly interfaces, can also influence usage. There is wide provision of clinical guidelines in many chronic diseases, but the uptake and use of such guidance varies enormously. There are many hurdles to overcome in optimising the utility of guidance, ranging from awareness of its existence to implementation and impact on individual care. Low awareness will always result in low adherence but, even with detailed plans and processes for implementation, clinician knowledge of such guidelines is relatively low worldwide for osteoporosis and other chronic diseases. Education is obviously important but its effectiveness can be disappointing. The wider use of electronic health care systems and health records may lead to improved adherence to clinical guidance due to automation. Certainly computergenerated reminders appear to improve adherence to protocols. A number of guidelines also provide clinical decision support systems, usually in the form of software programs, to assist with uptake and implementation. In the UK, guidance on the assessment of osteoporosis and fracture risk is provided by the National Osteoporosis Guideline Group (www.shef.ac.uk/NOGG) with a user-dependent interaction transferring the FRAX result to the NOGG website. In a recent analysis, 82 % of use of the NOGG website was found to arise from sites within the UK, demonstrating that some users of FRAX in other countries make use of the NOGG guidance. Almost all (95.7 %) of the UK sessions arose from calculations being passed through from the FRAX tool to the NOGG website, comprising FRAX calculations in patients without a BMD measurement (74.5 %) or FRAX calculations with a BMD result (21.2 %). National Health Service (NHS) sites were identified as the major source of visits to the NOGG website, comprising 79.9 % of the identifiable visiting locations, but this is an underestimate as many sites from within the NHS are not classified as such. The analysis showed widespread and linked use of the FRAX and NOGG approaches to assessing and managing fracture risk in patients in the UK. The approach is one that could readily be applied in other countries within Europe and beyond through the existing FRAX models, an option that has already been exercised by several countries (e.g. Finland, Lebanon and Romania). The impact on appropriate prescribing and fracture rates should be the focus of future studies. A wide range of biochemical markers provide information on the activities of bone cells, largely osteoclasts and osteoblasts, commonly termed bone turnover markers (BTM). They divide into two main categories, markers of bone cells and type I collagen formation or breakdown products. Robust assays for many markers have been adapted to automated biochemical platforms making them rapidly and cost-effectively available in clinical laboratories. Their analytical performance has been demonstrated to quantify biologically significant changes in serum/plasma or urine depending on the analyte. The specificity of BTMs for bone cell activities has markedly increased over recent times. For example the assay for Ctelopeptide fragments of collagen type I a1 chains (serum CrossLaps (ß-CTX)) is specific for not only the crosslinking of type 1 collagen between lysine residues in adjacent type I collagen molecules but also for the isomerization of the arginyl peptide to the β-form which can only take place in the mature collagen of bone. This marker therefore is highly specific for bone resorption. However there is marked variability of BTMs. Pre-analytical variation arises from the use of serum vs. plasma samples or the urine collection procedure. Analytical variability can arise from assays from different manufacturers. There is a large biological variability depending on the status of the subject including seasonality, sex, age and menopausal or disease status. BTM levels can vary across the 24-hour period particularly associated with food intake. These acute factors are more significant for bone resorption BTMs and probably reflect acute changes to osteoclast activities although such changes have not been clearly proven. There is interest in the clinical use of bone turnover markers, limited by the biological and analytic variability. Bone markers have a potential use in monitoring response to therapies. A greater decrease in bone turnover markers of resorption is associated with a greater increase in spinal bone density. In contrast changes in BMD with therapy are slow and modest and correlate less closely to the fracture risk reduction than changes in BTMs, particularly with antiresorptive therapy. A bone marker may also be a useful indicator early of treatment noncompliance or secondary osteoporosis. Bone turnover markers also have a potential use to predict fracture risk independently of BMD. To address the limitations of variability, the International Osteoporosis Foundation (IOF) and National Bone Health Alliance (NBHA) in the United States have implemented a number of complimentary activities around the harmonization and standardization of the use of these markers. Goals include: 1. Lab result reporting should be consistent from laboratory to laboratory 2. Minimizing variability through similar language for sample type (EDTA plasma), collection and storage/ transportation 3. Aligning Lab values around the common reference range for appropriate postmenopausal women and men 4. Development of standard reference bone turnover markers and reference analytes The IOF and the international Federation of Clinical Chemistry (IFCC) support one marker of bone formation, procollagen type I N propeptide or s-P1NP and one marker of bone resorption, serum C-terminal telopeptide of type I collagen or s-CTX to be used as standard reference bone turnover markers in clinical studies. This will allow us to compare the performance of alternative markers and enlarge the international experience of the application of markers to clinical medicine. A comparison study of assays for CTX and PINP in current clinical laboratory use will be undertaken. Each of four European centres will collect specimens from up to 200 patients attending an osteoporosis clinic. The study will collect data on pre-analytical factors including serum or plasma, fasting and non-fasting and sex on the relationship between values obtained from Roche and IDS CTX assays and Roche, IDS and Orion Diagnostica PINP assays.
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The regression equations describing the relationships between each of the assays for CTX and PINP will be compared with published to data with the aim of reaching consensus equations for the each of these BTMs. Sarcopenia and osteoporosis increase the risk of suffering falls and fractures respectively. Bone and muscle are closely interconnected not only anatomically, but also physically, chemically and metabolically. Indeed, a significant proportion of individuals with sarcopenia also suffer from osteopenia/ osteoporosis suggesting a link between the two tissues. The simultaneous occurrence of osteoporosis and sarcopenia (osteosarcopenia) has been observed in a subset of frailer individuals at higher risk of disability, falls and fractures.
The mechanisms that explain the synchronic loss of bone and muscle mass are multiple: 1) low muscle mass is associated with abnormal glucose metabolism and changes in musclerelated proteins, known as myokines, which have a direct effect on bone metabolism; 2) decreased muscle strength and physical performance is associated with low mechanical loading thus directly affecting bone mass; and 3) both muscle and bone are infiltrated by fat, which has a toxic effect on cell function and survival. In this session, we will review the current knowledge on the common biological mechanisms of osteosarcopenia and summarize those biochemical features that are prevalent in osteosarcopenic subjects. We expect that this information could be used to understand the clinical features of osteosarcopenia, to inform the design of future trials, and to develop interventions for this particular syndrome. Objective: Falls and fractures increase with age, and adversely impact the independence and well-being of older adults. Both sarcopenia (SP) and osteoporosis contribute to falls/fracture risk; because of this, the term osteosarcopenia (OS) has been coined. Additionally, obesity is been a risk factor for falls and fractures. Rather than focusing on each disease individually, it is logical that opportunity exists to combine clinical factors to potentially improve identification of older adults at risk for falls and fractures. We termed such a combination "dysmobility syndrome" (DS). The aim of this study was to compare DS prevalence to OS prevalence using various current SP definitions. Materials and Methods: Community-dwelling older adults underwent DXA to measure BMD, lean and fat mass and performed various muscle function tests. OS was defined by a BMD T-score of≤ −2.5 plus meeting one of various SP definitions (EWGSOP, International, and FNIH). DS risk factors included BMD T-score, appendicular lean mass (ALM)/height2,% body fat, grip strength, gait speed, and a history of falls. Each risk factor received one point, a value ≥ 3 was defined as DS. Pearson chi-squared analyses were used to compare disease prevalence using the various definitions.
NS30 POTENTIAL CLINICAL APPROACHES TO THE DIAGNOSIS OF OSTEOSARCOPENIA/DYS-MOBILITY
Results: In 197 adults (132 F/65 M; mean age 80.5 years) OS prevalence ranged from 0.5 % (using FNIH cutoffs) to 6.6 % (using EWGSOP). DS prevalence was 34 % and significantly higher than all OS definitions (p < 0.01). Of those who had fallen within the last year, 51 % met our DS definition, whereas 0.0-0.04 % met OS definitions. Conclusion: DS prevalence was significantly higher than OS prevalence in this cohort. Additionally, it was also higher in those with a previous fall. Objective: Explore the integration of DXA limitations and practice handling for fracture risk calculation and patient selection. Material and Methods: This symposium is divided into 03 sessions opened to audience participation. The presenters are experts Ben-Hur Albergaria, Cristiano Zerbini and Bruno Muzzi Camargos. Discussion: 1st Session -Prof. Ben-Hur Albergaria (20 min.) 1.1. Parallax Effect, Areal and Volumetric BMD DXA systems produce collimated X-ray beam to avoid diverging X-rays and provide better energy absorptiometry. Although X-ray dispersion is minimized through pinholes, there is a residual dispersion that leads to a parallax effect. Parallax is a displacement on the projected size of a given object. Parallax effect tends to overestimate bone area and is minimized on narrow fan beams.
DXA systems estimate BMD from bone area, on a bidimensional way. Thus, it estimates areal BMD (aBMD). Other technologies like QCT estimate the volume BMD (vBMD). Compared to vBMD, aBMD underestimates BMD on smaller bones. Therefore, shorter bones might have the same true volume BMD but lower the aBMD. It is especially relevant for short-stature individuals and children. It also may explain higher aBMD values for men compared to women. 1.2. DXA Artifacts and Limitations Buttons, zippers and other dense artifacts on clothes must be avoided on DXA acquisition. Less dense artifacts such as soft elastic underwear bands may also compromise DXA results. Elastic band retraction from classical ROIs should be encouraged on DXA acquisitions. When the BMD of adjacent vertebra differs from each other in more than 1.0 DP T-score, it is recommended to exclude the vertebra with the highest T-score to minimize artefactual effects of high density degenerative disorders on the spine. Adequate vertebrae exclusion enhances patient's fracture risk prediction. 1.3. Precision Error Calculation and Use DXA precision error affects bone mass monitoring. Part of this variation derives from patient positioning and analysis. This session addresses standard procedures to estimate least significant change (LSC) and its role on clinical monitoring by DXA. Conclusion: DXA, FRAX and TBS integration comprises a helpful merging of resources to help patient selection. The use of this helpful combination demands acknowledge of DXA artifacts, FRAX cutoff validation and TBS procedure standardization. Once these issues are appropriately addressed, the result is a suitable combination of independent parameters, resulting on more cost-effectiveness and beneficial interventions. This symposium is divided into 03 sessions opened to audience participation. The presenters are experts on the topics addressed. The content was developed to cover relevant aspects of the tools mentioned above. Discussion: 2nd Session -Prof. Cristiano AF Zerbini (10 min.) 2.1. Fracture Risk Prediction Tools Models for FRAX™ calculation tool were developed upon 6 Latin American countries: Argentina, Brazil, Chile, Colombia, Ecuador and Mexico. Besides other tools have been developed, it is clear that FRAX™ is the one most widely used around the globe. Fracture probability differs greatly in different parts of the world and adjustments are countryspecific. Thus, lacking of good epidemiological data is a limitation for FRAX™ use. When there is lacking of good quality data, one country shall adopt other countries' algorithms. In order to lessen those differences and provide a better determination of cutoffs used for drug intervention, FRAX™ has been validated through prospective epidemiological studies. This session addresses how these differences impact risk calculation and what can be performed to adjust FRAX according to specific regions and populations. Conclusion: DXA, FRAX™ and TBS integration comprises a helpful merging of resources to help patient selection. The use of this helpful combination demands acknowledge of DXA artifacts, FRAX™ cutoff validation and TBS procedure standardization. Once these issues are appropriately addressed, the result is a suitable combination of independent parameters, resulting on more cost-effectiveness and beneficial interventions. Introduction: DXA, FRAX and TBS are fully integrated into a single platform that provides a better selection of patients highly benefitted from pharmacological treatment. DXA artifacts on acquisition and analysis, lacking of epidemiological validation for FRAX cutoffs and misuse of standard TBS procedures can compromise the ultimate patient risk calculation.
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Objective: Explore the integration of DXA, FRAX and TBS, their limitations and practice handling for fracture risk calculation and patient selection. Material and Methods: This symposium is divided into 03 sessions opened to audience participation. The presenters are experts on the topics addressed. The content was developed to cover relevant aspects of the tools mentioned above. Discussion: 3rd Session -Prof. Bruno Muzzi Camargos (10 min.) TBS has been widely available and incorporated into clinical practice as a relevant resource to enhance DXA capability to identify patients with poor trabeculae distribution, thus more prone for fracture, independent of bone mass. Several studies and meta-analysis demonstrated TBS contribution for easy bone quality access. Recently, TBS showed its ability to enhance FRAX on fracture risk and also on death prediction. This session addresses how TBS can be used to enhance thresholds recommended on drug intervention guidelines on a clinical setting. Conclusion: DXA, FRAX and TBS integration comprises a helpful merging of resources to help patient selection. The use of this helpful combination demands acknowledge of DXA artifacts, FRAX cutoff validation and TBS procedure standardization. Once these issues are appropriately addressed, the result is a suitable combination of independent parameters, resulting on more costeffectiveness and beneficial interventions. This will be a clinically-oriented, interactive, case-based session, covering four of the current clinical conundrums in osteoporosis management. The cases will centre around the following clinical management issues using 'real life' case scenarios: Assessment of risk of fracture in practice; decision-making in patients with fragility fracture in patients already taking long-term bisphosphonates; prevention of fracture among people with gastro-oesophageal reflux; and management of atypical fractures.
NS35 CLINICAL CONUNDRUMS IN OSTEOPOROSIS MANAGEMENT
The audience will be actively involved in this session, with plenty of opportunity to ask questions and give opinions. The incidence of vertebral fragility fractures and deformity increase steeply with age. Every sixth woman and every twelfth man will sustain a symptomatic vertebral fracture. Vertebral fractures result in pain, functional disability and decreased quality of life, which may last for several years, and may also affect mortality. The patient with an acute fracture should be examined with radiology for diagnosis. In case of a low-energy fracture, osteoporosis should be suspected and investigated. Adequate pain management should be instituted. The evidence for the use of vertebroplasty or kyphoplasty is weak. Brace treatment have been suggested for pain relief, but evidence for its effect is lacking. In the rare event of neurological compromise, or unstable fractures, surgical treatment should be considered.
NS36 VERTEBRAL FRACTURES IN AN ORTHO-PEDIC PERSPECTIVE
NS37 SARCOPENIA AND OSTEOPOROSIS -THE HAZARDOUS DUO
T. Cederholm 1,2 1 Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden, 2 Department of Geriatric Medicine, Uppsala University Hospital, Uppsala, Sweden
In the ageing societies it is crucial to identify factors that limit the health and functional capacity among the older adults. Sarcopenia and osteoporosis are emerging such factors that either are underestimated (osteoporosis) or not observed at all (sarcopenia) in today's medical community. The two conditions are strongly linked from an etiologic point of view, their negative consequences in the form of falls and fractures are equally linked and many treatment modalities are common. Diagnostic procedures overlap. Bone mineral density is measured by dual energy x-ray absorption (DXA), and this measurement also gives information on body composition, such as lean body mass. The combination of reduced muscle mass and reduced muscle function provides the diagnosis of sarcopenia. Primary sarcopenia and primary osteoporosis are age-related, whereas their secondary forms could be disease-related, nutrition-related or activity-related. These etiologic mechanisms indicate the potential treatment modalities, whereof several are life-style related such as nutritional provision of proteins and vitamin D, as well as exercise; i.e. strength and endurance. The increased awareness of the hazardous duo of sarcopenia and osteoporosis may provide a foundation for better care (and prevention) of the growing older segments of the population. Vertebral fractures, the most common clinical manifestation of spinal osteoporosis, is one of the main reasons for kyphosis and have a significant and prolonged impact on health-related quality of life. Increased thoracic kyphosis predisposes the individual to chronic pain, height loss and respiratory problems. The efficacy of a back muscle training program on back muscle extensor strength, kyphosis, height and thoracic expansion was evaluated in 36 women with osteoporosis and vertebral fracture. The participants were randomized to a training or control group. The group training program was performed twice a week for 4 months and was led by a physiotherapist. A per-protocol analysis that included 28 women showed that back muscle extensor strength and thoracic expansion increased in the training group, while body height decreased in the control group. A qualitative interview study was carried out and showed positive experiences from the group training program by improved mobility and sleep, increased strength and physical activity, and reduced pain. Our findings, based on quantitative and qualitative methods, show that professionally supervised back muscle training brought benefits to everyday life, increased well-being, and constituted a complement to pharmacological therapy for this group of women.
NS38 VERTEBRAL FRACTURES IN AN OSTEO-POROTIC PERSPECTIVE, SYMPTOMS AND WHAT TO DO
NS39 TRAINING PROGRAM PRESENTATION
A. Dahlgren Sarcopenia (from the Greek sarx:flesh, penia:loss) is an evolving concept related to the decrease of functional performance during the daily living activities that lead to impairment to personal independency, falls and fractures. It is related to nutritional, age related (frailty) and associated disease factors. As the age of the populations increase sarcopenia and frailty are very important public health problems all over the World. After the age of 50 muscle mass loses 1 % per year. The European Working Group on Sarcopenia in Older People (EWGSOP) developed a clinical definition and consensus diagnostic criteria for age-related sarcopenia using the presence of both low muscle mass and low muscle function (strength or performance) In a recent community dwelling study developed in UK in older adults with an average age of 67 years prevalence of sarcopenia was 4.6 % in men and 7.9 % in women using the EWGSOP approach. Sarcopenia is an important independent predictor of disability in population -based studies linked to poor balance, gait speed, falls and fractures. Some Latin American countries are developing data base of muscle mass and strength using DXA, grip strength and other physical performance tests. Preliminary data will be showed during this symposium.
NS41 POSTMENOPAUSAL WOMEN WITH SAR-COPENIA HAVE HIGHER PREVALENCE OF OSTEOPOROTIC FRACTURES
consulted in an Institution specialized in Osteoporosis. Secondary, describe the association between sarcopenia and prevalent fractures, falls, physical activity and vitamin D status. Methods: Between January and October 2015, 211 ambulatory women were evaluated. All patients underwent DXA scans (lumbar spine, hip and total body) to measure muscle mass, hand grip dynamometry, chair stand test and 4 mts walk gait speed to measure muscle strength and performance. All clinical factors related to bone health were consigned by a specialized physician. Results: Cohort median age was 70.5 ± 7.9 years (media ± SD), 37 (17.5 %) patients fulfilled EWGSOP criteria and 174 did not (non sarcopenia group). Women with sarcopenia have significant lower weight (56.3 ± 8.9 vs. 62. 5 ± 10. 9 kg, p < 0.01); BMI , p < 0.01). Fifteen (40.5 %) sarcopenic women had positive osteoporotic fracture history vs. 25 (14.6 %) of no sarcopenic women, p < 0.01. Nineteen sarcopenic patients (51.4 %) referred having had a fall in the last year vs. 63 (36.2 %) (p: 0.09). There were no significant differences between the groups regarding age (71.2 ± 8.4 vs. 70.3 ± 7.9 years, p:0.54), height, vitamin D values (32.2 ± 13.9 vs. 31.6 ± 10.4 ng/ml, p: 0.85), total body fat, LS BMD, osteoporosis in any DXA region (19 (52.8 %) vs. 70 (41.9 %), p 0.23) or referred physical activity. BMI correlates positively with appendicular muscle mass index and negatively with chair stand test and gait speed. Conclusion: In this group of ambulatory women older than 60 year old who consulted in an Institution specialized in osteoporosis, 17.5 % met EWGSOP criteria for diagnosis of sarcopenia. Sarcopenic women had significantly higher osteoporotic fractures prevalence and a tendency of higher fall history in the last year. The principal aim of this communication is highlighting the importance of evaluating muscle mass and function in women with osteoporosis and high fracture risk. Summary: The criteria most used for the definition of sarcopenia, those based on the ratio between the appendicular skeletal muscle mass (ASM) and the square of the heigh (h2) underestimate prevalence in overweight/ obese people whereas another criteria consider ASM adjusted for total fat mass. We have shown that ASM adjusted for fat seems to be more appropriate for sarcopenia diagnosis. Introduction: Since the prevalence of overweight and obesity is a growing public health issue, the aim of this study was to evaluate the prevalence and risk factors associated with sarcopenia, based on these two criteria, among older women. Methods: Six hundred eleven community-dwelling women were evaluated by specific questionnaire including clinical data. Body composition and bone mineral density were evaluated by dual X-ray absorptiometry. Logistic regression models were used to identify factors independently related to sarcopenia by ASM/h2 and ASM adjusted for total fat mass criteria.
Results: The prevalence of overweight/obesity was high (74.3 %). The frequency of sarcopenia was lower using the criteria of ASM/h2 (3.7 %) than ASM adjusted for fat (19.9 %) (P < 0.0001). We also note that less than 5 % (1/23) of sarcopenic women, according to ASM/h2, had overweight/obesity, whereas 60 % (74/122) of sarcopenic women by ASM adjusted for fat had this complication. Using ASM/h2, the associated factors observed in regression models were femoral neck T-score (OR = 1.90; 95 % CI 1.06-3.41; P = 0.03) and current alcohol intake (OR = 4.13, 95 % CI 1.18-14.45, P = 0.03). In contrast, we have identified that creatinine (OR = 0.21; 95 % CI 0.07-0.63; P = 0.005) and the White race (OR = 1.81; 95 % CI 1.15-2.84; P = 0.01) showed a significant association with sarcopenia using ASM adjusted for fat.
Conclusions:
In women with overweight/obesity, ASM adjusted for fat seems to be the more appropriate criteria for sarcopenia diagnosis. This finding has relevant public health implications, considering the high prevalence of overweight/ obesity in older women. Inflammatory cytokines particularly enhance bone loss by activation of osteoclast differentiation factors such as macrophage colony-stimulating factor (M-CSF) and RANK ligand and by molecules which interfere with bone formation such as dickkopf Wnt signaling pathway inhibitor 1 (Dkk1) and sclerostin. In OA the local accumulation of insulin growth factor-1 (IGF-1), which is a potent stimulator of bone formation, contributes to the subchondral bone sclerosis in OA. Furthermore, IL-6, prostaglandin-E2 and receptor activator of nuclear factor κ-B ligand (RANKL) may be responsible for increased number of osteoclasts in OA and bone resorption. OA experimental models have showed that cytokines regulate bone formation and interaction of osteoclasts with the bone substrate which also provides a potent signal to induce the osteoclast differentiation. Several animal models have highlighted the role of BMP and Wnt signaling in the process of ankylosis in SpA patients. Human data further supported these animal observations. Conclusion: Osteorheumatology is a new scientific discipline which is rapidly evolving, studying the mutual effects of the skeleton and immune systems at the cellular and molecular levels, both in physiologic as in pathologic conditions.
NS43 TOTAL AND APPENDICULAR LEAN BODY MASS REFERENCE VALUES BY DUAL-ENERGY X-RAY ABSORPTIOMETRY AMONG HEALTHY MEXICAN POPULATION
NS47 INTRODUCTION TO MEDICATION ADHER-E N C E , P R E F E R E N C E A N D S H A R E D -DECISION MAKING
M. Hiligsmann Poor adherence with therapy is a major obstacle in osteoporosis management that may partially be due to unaddressed patient values and preferences. The patient perspective is nowadays becoming increasingly important in clinical and policy decisions. Addressing patients' concerns with treatment and involving them in clinical decision-making may lead to improved adherence with therapy. Our patients want to be informed by their doctors and play an active role in clinical decision making. The 21th century is becoming the age of preference based medicine in which the clinicians become the experts on the medical options, while patients bring in their values and preferences. This 'patient centered care' requires a whole new area of research into patient reported outcomes and even more into methods to assess preferences, and in approaches to incorporate preferences in the medical office. The aim of this presentation is to introduce and review the concepts of medication adherence, preference and shared-decision making. First, background information on medication adherence including definition, burden, implications and determinants will be described. Existing programs to improve adherence in osteoporosis as well as the economic value of improving adherence in osteoporosis will then be presented. Second, the value to assess preferences in health care and methods used to elicit patients' preferences will be reviewed and discussed. Finally, the increasing importance of shared-decision making and its fundamental components will be introduced. All these concepts could have substantial potential for clinicians in order to improve poor medication adherence and could also be very useful for policy decisions and guideline development. Poor medication adherence is a major problem in osteoporosis and may have influence on subsequent fracture rates and mortality despite of the osteoporosis treatment. Data on patient preferences could help clinicians to improve medication adherence and could also be useful in policy decisions and guideline development. We performed a review (1) to identify literature reporting on the preferences of patients for osteoporosis drug medications. Several methods have been used to elicit patient preferences for medications and their characteristics including qualitative research, survey with ranking/rating exercises, discrete-choice experiments and clinical studies (crossover designs, open-label study). This review showed that although effectiveness and side effects were, not surprisingly, important considerations in treatment preferences, frequency of administration (and in particular less frequent dosing regimens) is also highly valued by patients. Understanding patients' preferences and incorporating them in clinical decision making could lead to improved osteoporosis care. Reference: 1. Hiligsmann M, et al. Curr Rheumatol Rep 2015; 7: 61.
NS49 FROM GROUPS TO INDIVIDUALS: FROM P R E F E R E N C E S T U D I E S T O S H A R E D DECISION MAKING IN THE CLINICAL SETTING
A. Boonen Background: The literature on patient preferences for interventions shows important variation in preferences of individual patients. In other words, results of preference studies conducted on the 'group level' cannot simply be applied to the 'individual' patient. Moreover, when embracing shared decision making, there are challenges to explain patients the different treatment options, and to support them when trading-off the different characteristics of the possible treatments. Therefore, patient decision tools are needed to allow rationale involvement of patients in treatment decisions. Methods: The development of a decision tool requires clear identification of the scope, an appropriate development/design of a prototype, alpha testing among professionals and patients by semi-structured interviews and beta testing in larger groups of patients. The application of a decision tool in clinical practice requires possible training of nurses or rheumatologists that administrated the tool. Before widespread implementation of patient decision aids insight into their effectiveness on different outcomes is needed. Results: Several decision aids are available for use in osteoporosis and development of one of these decision tools will be presented in more detail. The role of healthcare professionals in the process of shared decision making is important in the success of preference based healthcare. The use of decision tools significantly improves patients' knowledge about the available options and reduces decisional conflict. There is a variable effect of DAs on the uptake of medication. Conclusions: In view of large heterogeneity in patient preferences for osteoporosis treatment, individual decision tools are needed to support patients in their decision. Despite increasing evidence about the usefulness of patient decision tools, there remains a sense of ambivalence among healthcare professionals on the utility and benefits of decision tools. The orthogeriatric approach is a model of care to provide global support to elderly patients with hip fractures, in order to allow to live an active life. In the orthogeriatric approach clinical problems are managed by the geriatrician while the orthopaedic surgeon is responsible for surgical treatment. Several models for organizing the cooperation between orthopaedic and geriatric staff exist, but the most effective seems to be the orthopaedic/geriatric comanagement. Fragility Fracture Network (FFN) was born with the aim of spread throughout the world the orthogeriatric approach. FFN is an international organization that has a vision: a world where anybody who sustains a fragility fracture achieves the optimal recovery of independent function and quality of life, with no further fractures. The mission is to optimize globally the multidisciplinary management of the patient with a fragility fracture, including secondary prevention. The goals of FFN are: to create a global network of national alliances of fragility fracture activists, to spread globally the best multidisciplinary practice and systems of care, to ensure that every fragility fracture becomes an opportunity for preventing further fracture, to promote research aimed at improving the quality of fragility fracture care, to generate political priority for fragility fracture care in all countries. The orthogeriatric model at S. Andrea Hospital in Rome is a geriatric ward comanaged with orthopaedics. The patient with hip fracture is 83,2 ± 9,2 years, 82 % are female. The average numbers of comorbidities are 5,2+ 2,3; cognitive impairment is present in 39 % of patients, hypertension by 79 %, diabetes by 32,2 %. The 8.7 % of the population has a previous hip fracture. The mean value of vitamin D is 8,4 ± 6,3 ng/ml. In conclusion the orthogeriatric approach should be viewed as a radical alternative to the traditional model of care. In each hospital, the orthogeriatric unit should represent a center of excellence for treating elderly patients with fragility fractures. The management of fragility fractures require special consideration in terms of surgical management. Initially the majority of surgical devices and implants were developed from the perspective of young active persons with normal bone; however, the increasing incidence of fragility fractures demanded technological innovations in the field of fracture-related implants. The objectives of the presentation is to provide an overview of recent advances. Fundamental improvements have occurred over the past years particularly in the management of hip fracture patients as a direct consequence of research; the largest randomized controlled trial on treatment of femoral neck hip fractures comparing pins or screws and hip replacement entirely changed practice in Sweden. Hip replacement, either total or hemiarthroplasty vastly reduced secondary procedures while improving mobility and quality of life. It also demonstrates the value of surgical registers to monitor and continuously improve health care, hence data from the National registries for hip replacement, the very first registry established in 1979 and the hip fracture register are influencing treatment around the world. Similarly, the management of trochanteric fractures now includes locking plates and intramedullary nails. A recent novel treatment principles utilizes the possibility to lock the screws to the plates and is one of the more beneficial techniques in fragile bone. This specific method is particularly useful at the ends of long bones where the cortex is thinning and the trabecular bone content high; also the most common sites for fragility fractures such as proximal humerus, distal radius, distal femur or proximal tibia. This method is contrary to previously used of sliding screws, which has other advantages. Furthermore, for complex shoulder fractures in relatively younger women, product development in joint replacement can even further enhance post-fracture functioning and continued ability to work for many. Displaced distal radius fractures may have a better outcome with the use of small plates or pinning, nevertheless, using a plaster cast may still provide sufficient alignment for healing in the very elderly as observed by patientrelated outcome instruments. The most important aim for patients at the age of 50 years or above after sustaining a fragility fracture ideally is to regain the level of mobility and independence before the fracture occurred. To reach this aim a multidisciplinary and multifactorial comprehensive rehabilitation program should be provided in each patient. Early mobilization following surgery is critical for a patient's functional independence and prevention of postoperative complications. Initiation of physical therapy should preferably start on the first postoperative day. Based on the initial condition of the patient, an appropriate physical therapy includes upper-and lower-extremity strength exercises, gait training (e.g. on a treadmill), balance and functional training (e.g. ambulation and stair climbing) as well as aerobic exercises and stretching for tight soft tissues and joints. An accompanying occupational therapy with the patient and family should include functional mobility, adapted activities of daily living, adaptive equipment use, transfer training, fall prevention, and home safety/modification. Multifactorial fall prevention strategies should start in the inpatient setting containing the improvement of balance, muscle strength and functional performance including occupational ADL training, assessment and treatment of fall risk factors (e.g. inappropriate medication, visual and hearing deficiencies), assessment of nutritional status and supplement of calcium and vitamin D. Additionally, a single home visit by an occupational therapist after discharge significantly reduces the risk of further falling. It is important to consider, that part of the patient's training improvements will be lost after stopping exercise (detraining effects). Therefore, home-based or community-based exercise programs should follow inpatient rehabilitation. This should include multifactorial and multidisciplinary supervision, as well as continuing the progressive muscle strength training, balance, and functional training. The Fragility Fracture Network (FFN) aims for multidisciplinary and multiprofessional developed recommendations and ways to implement them. The case for Fracture Liaison Service (FLS) for the prevention of secondary fractures is clear. With an ageing population, the burden of osteoporosis is set to increase. Despite evidence for the clinical effectiveness of secondary fracture prevention, translation in the real-world setting remains disappointing: worldwide, eighty per cent of fragility fracture patients are neither assessed nor treated for osteoporosis or falls risk to reduce future fracture incidence. Where implemented at all, a wide variety of service models are used to deliver effective secondary fracture prevention. To support and promote the use of effective models of care across the globe, the International Osteoporosis Foundation (IOF) launched the Capture the Fracture ® (CTF) programme in 2013. This expert-led and evidence based programme aims to reduce secondary fractures by facilitating the implementation of FLS on a global level. A primary resource developed by CTF is the Best Practice Framework (BPF) which sets standards for FLS, serves as a benchmark for existing FLS and serves as a guidance tool for developing FLS. In an effort to engage the global medical community, CTF offers a Best Practice Recognition programme where FLS can submit their service to IOF for evaluation against the BPF for a gold, silver or bronze star in recognition of achievements. The FLS is then included in the showcase of best practice and plotted on the CTF Map of Best Practice that displays participating FLS and their respective achievement level. To influence change, the map can be used as a visual representation of FLS available worldwide, their achievements, as well as the areas for opportunity and development in secondary fracture prevention. After a year of implementation, FLS from 60 hospitals across six continents were analysed and initial findings confirmed that a single framework with set criteria is able to benchmark services across healthcare systems worldwide.
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